Difference between revisions of "Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8475)"

Latest revision as of 12:16, 23 May 2020

Publication: "Targeting cancer stem cell pathways for cancer therapy" published as Signal Transduct Target Ther; 2020 ; 5 8; DOI: 10.1038/s41392-020-0110-5

Language	Label	Description	Also known as
English	Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)	Publication: "Targeting cancer stem cell pathways for cancer therapy" published as Signal Transduct Target Ther; 2020 ; 5 8; DOI: 10.1038/s41392-020-0110-5

Statements

instance of

Segment

0 references

occurs in

Targeting cancer stem cell pathways for cancer therapy (DOI: 10.1038/s41392-020-0110-5)

0 references

part of

Targeting cancer stem cell pathways for cancer therapy (DOI: 10.1038/s41392-020-0110-5)

0 references

Section or subsection level in publication

Table appearing in a publication

0 references

IMRaD(C) Section

Introduction

0 references

Has Sectioning

Section 1: Introduction (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 2.1: Biological characteristics of CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 2.2: Isolation and identification of CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.1: Major transcription factors in CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.2.1: Wnt signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.2.2: Notch signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.2.5: JAK-STAT signaling pathway (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.2.6: TGF/SMAD signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.2.8: PPAR signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.2.9: Interactions between signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.3: The microenvironment of CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.3.1: Vascular niche microenvironments and CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.3.2: The hypoxia microenvironment and CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.3.3: Tumor-associated macrophages and CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.3.4: Cancer-associated fibroblasts and CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.3.5: Cancer-associated MSCs and CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.3.6: Extracellular matrix and CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 3.3.7: Exosomes in the TME and CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 4: Therapeutic targeting of CSCs (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 4.1: Agents targeting CSC-associated surface biomarkers in clinical trials (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 4.2: Agents targeting CSC-associated signaling pathways in clinical trials (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 4.3: Targeting the CSC microenvironment (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 4.4: CSC-directed immunotherapy (from DOI: 10.1038/s41392-020-0110-5)

0 references

Section 5: Conclusions and perspectives (from DOI: 10.1038/s41392-020-0110-5)

0 references

Competing interests (from DOI: 10.1038/s41392-020-0110-5)

0 references

Bibliography (from DOI: 10.1038/s41392-020-0110-5)

0 references

Sitelinks

⧼wikibase-sitelinks-sliswiki⧽(1 entry)

sliswiki Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)

@@ Property / Has Sectioning @@
+Section 4.1: Agents targeting CSC-associated surface biomarkers in clinical trials (from DOI: 10.1038/s41392-020-0110-5)
+Normal rank
@@ Property / Has Sectioning @@
+Section 4.2: Agents targeting CSC-associated signaling pathways in clinical trials (from DOI: 10.1038/s41392-020-0110-5)
+Normal rank
@@ Property / Has Sectioning @@
+Section 4.3: Targeting the CSC microenvironment (from DOI: 10.1038/s41392-020-0110-5)
+Normal rank
@@ Property / Has Sectioning @@
+Section 4.4: CSC-directed immunotherapy (from DOI: 10.1038/s41392-020-0110-5)
+Normal rank
@@ Property / Has Sectioning @@
+Section 5: Conclusions and perspectives (from DOI: 10.1038/s41392-020-0110-5)
+Normal rank
@@ Property / Has Sectioning @@
+Competing interests (from DOI: 10.1038/s41392-020-0110-5)
+Normal rank
@@ Property / Has Sectioning @@
+Bibliography (from DOI: 10.1038/s41392-020-0110-5)
+Normal rank

Difference between revisions of "Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8475)"

Latest revision as of 12:16, 23 May 2020

Statements

Sitelinks

⧼wikibase-sitelinks-sliswiki⧽(1 entry)

Navigation menu

Personal tools

Namespaces

Variants

Views

More

Search

Navigation

Tools

In other languages